Injectable Vitamin D3 Products Recalled for Lack of Sterility Assurance
Pharmacy Innovations is recalling injectable Vitamin D3 products nationwide due to insanitary facility conditions that compromised sterility assurance. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves injectable medications where sterility cannot be assured due to facility sanitation failures. While no illnesses have been reported, injectable products with compromised sterility assurance represent a risk-of-harm scenario, meeting the rubric criterion for High severity.
Plain-English summary
Pharmacy Innovations is recalling injectable Vitamin D3 products distributed nationwide: Vitamin D3-Aqueous 10,000 IU/mL and Vitamin D3-PF-Ethyl Oleate 50,000 IU/mL (1 mL vials). Both are prescription medications.
The recall was initiated following an FDA inspection that discovered insanitary conditions at the Pharmacy Innovations facility in Erie, Pennsylvania. These conditions raise concerns about the ability to assure sterility for injectable products manufactured under those conditions.
Patients who have received these products should contact their healthcare provider. Healthcare providers should identify affected patients and remove recalled products from inventory. The products are identified by specific lot codes: t20221017@25 and t20221013@15. No illnesses or adverse events have been reported in connection with these products.
The recalled product
- Product
- VITAMIN D3-AQUEOUS- 10,000IU/ML (1ML VIAL) INJECTABLE; VITAMIN D3-PF-ETHYL OLEATE- 50,000IU/ML (1ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Injectable
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221017@25 t20221013@15
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27